Please login to the form below

Not currently logged in
Email:
Password:

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Blind man's buff

Blind man's buff

In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.

Latest news

More from news
Approximately 23 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • The gold standard of scientific evidence The gold standard of scientific evidence

    PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.

  • Digital disruption Digital disruption

    best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical

  • The price is right? The price is right?

    IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics